Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

StatusActive, Not Recruiting
PhasePhase 4
Started

Record status This record was last updated April 9, 2026 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jul 1, 2025 to Apr 30, 2026v2 Show 5 more changesShow less
    • Start date changed from estimate of Mar 1, 2024 to Aug 1, 2024
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 50 to confirmed 41
    • Study sites: 1 to 3
    • Eligibility criteria expanded, about 31 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This study is an investigator-initiated, prospective, open-label, single-arm, multicenter clinical trial aimed at exploring the antitumor activity of Lorlatinib in ALK-positive NSCLC patients with brain/ leptomeningeal metastases.
Trial Details
NCT Number NCT06282874
Lead Sponsor Guangdong Association of Clinical Trials
Conditions
(from sponsor)		 Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
Related terms Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis
Enrollment 41 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov